LivaNova (NASDAQ:LIVN) Releases FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.200-4.300 for the period, compared to the consensus estimate of 4.100. The company issued revenue guidance of $1.4 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LIVN. Robert W. Baird decreased their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a research note on Thursday, February 19th. Mizuho increased their price target on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research note on Friday, March 27th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $66.00 price target on shares of LivaNova in a research note on Friday, January 9th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $77.22.

LivaNova Stock Up 6.3%

LIVN stock traded up $4.19 during trading on Thursday, hitting $70.45. 572,156 shares of the stock traded hands, compared to its average volume of 795,860. LivaNova has a 1 year low of $41.01 and a 1 year high of $71.92. The firm’s 50 day moving average is $63.97 and its two-hundred day moving average is $62.03. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of -15.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same period in the prior year, the firm posted $0.88 EPS. LivaNova’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts anticipate that LivaNova will post 3.66 EPS for the current year.

Key LivaNova News

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q1 results and guidance: LivaNova reported revenue of $362.3M and beat EPS estimates (reported $0.98 vs. consensus $0.85); management raised full‑year adjusted EPS guidance to $4.20–$4.30, above street consensus. The beat plus guide lift is the main bullish catalyst. MarketBeat Q1 release
• Positive Sentiment: Analyst upgrade/target boost: Mizuho raised its price target to $90 and kept an “outperform” rating, giving another near‑term upside signal for the stock. Benzinga The Fly
• Neutral Sentiment: Mixed analyst view: Robert W. Baird trimmed its price target slightly to $76 but maintained an “outperform” rating — still constructive but less bullish than Mizuho. Benzinga
• Neutral Sentiment: Guidance nuance: FY EPS guide was raised, but revenue guidance was given as roughly $1.4–$1.5 billion (slightly below some street expectations), which helps explain episodes of caution despite the EPS beat. MarketWatch
• Negative Sentiment: Conflicting/negative readouts: Some transcripts and reports briefly reported an earnings miss (one transcript flagged $0.41 EPS vs $0.85 expected) and several outlets noted shares initially slipped on cautious elements of guidance — this created short‑term volatility and explains mixed reactions. InsiderMonkey transcript Investing.com

Institutional Trading of LivaNova

A number of institutional investors have recently made changes to their positions in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after acquiring an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after acquiring an additional 36,094 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after acquiring an additional 15,405 shares during the period. Intech Investment Management LLC raised its position in shares of LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after buying an additional 7,195 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of LivaNova during the first quarter valued at approximately $130,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.